Letybo® receives FDA Approval for the treatment of glabellar lines
Croma-Pharma announced today that Hugel, Korean toxin manufacturer and partner of Croma, has received approval of the U.S. Food and Drug Administration (FDA) for Letybo® (letibotulinumtoxinA), the company’s botulinum toxin product.
Letybo® has secured FDA approval, positioning it as the sixth botulinum toxin achieving this milestone globally. This accomplishment leads to further product credibility and instills confidence among healthcare providers. Hugel will be one of only three global players that possesses licenses in the largest aesthetic markets US, Europe and China.
PRFDALET032024
